American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: http://www.sciepub.com/journal/ajmsm Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Sciences and Medicine. 2013, 1(3), 31-37
DOI: 10.12691/ajmsm-1-3-1
Open AccessArticle

Long-Term Electrolyte Effects during Initiation of Antihypertensive Therapy with Amlodipine or Hydrochlorothiazide in Diabetic Nigerians

Godfrey B.S. Iyalomhe1, , Eric K.I. Omogbai2 and Osigbemhe O.B. Iyalomhe2

1Mepco Schlenk Engineering College, Sivakasi, India

2Computer Science Department, HIAST (Higher Institute for Applied Sciences and Technology), Damascus, Syria

Pub. Date: April 14, 2013

Cite this paper:
Godfrey B.S. Iyalomhe, Eric K.I. Omogbai and Osigbemhe O.B. Iyalomhe. Long-Term Electrolyte Effects during Initiation of Antihypertensive Therapy with Amlodipine or Hydrochlorothiazide in Diabetic Nigerians. American Journal of Medical Sciences and Medicine. 2013; 1(3):31-37. doi: 10.12691/ajmsm-1-3-1

Abstract

Information is scarce regarding the effects of amlodipine or hydrochlorothiazide therapy on serum and urine electrolyte profiles in hypertensive Nigerians with type 2 diabetes mellitus. Therefore, to evaluate whether amlodipine or hydrochlorothiazide would be preferable to initiate treatment, we randomized 40 newly diagnosed hypertensive subjects with controlled type 2 diabetes mellitus aged 43-68years to amlodipine and hydrochlorothiazide treatment groups of 20 patients each (10 males, 10 females), and they were treated respectively, with amlodipine 10mg and hydrochlorothiazide 25mg, both drugs being given once daily for 48 weeks. Body mass index, blood pressure, 24h urine volume, serum and urine electrolytes were assessed at baseline and at the end of weeks 1, 3, 6, 12, 24, 36 and 48. The two drugs significantly reduced blood pressure, though the effect of amlodipine was significantly greater compared with that of hydrochlorothiazide (P < 0.01). Diuresis was significant in hydrochlorothiazide group (P < 0.01). Observed male/female serum Na+ loss was 9.18±2.32/10.90±2.50 and 13.30±1.34/15.10±1.77mmol/L for amlodipine and hydrochlorothiazide subgroups, respectively. There was a parallel significant (P < 0.05) natriuresis. Significant (P < 0.05) hypokalemia occurred in hydrochlorothiazide subgroups and overall male/female serum K+ loss was 0.10/0.08 and 0.16/0.24mmol/L for amlodipine and hydrochlorothiazide, respectively. However, there was no significant parallel kaliuresis. Significant (P < 0.05) disproportionate hypochloremia occurred in all subgroups, so also was the parallel chloriuria. By providing effective blood pressure control and beneficial biochemical effects, amlodipine therapy appears suitable for treatment of hypertension in these diabetic patients. Similarly, low dose hydrochlorothiazide therapy, which seems to have more marked effects in females, appears to have moderate biochemical complications in these patients and is, therefore, a logical alternative to substitute for or add to amlodipine therapy.

Keywords:
Amlodipine hydrochlorothiazide electrolyte effects hypertension type 2 diabetes mellitus Nigerians

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Wong, M.C.S., Jiang, J.Y., Ali, M.K., Fung, H., Griffiths, S., and Mercer, S.W., “Antihypertensive drug class and dyslipidemia: risk association among chinese patients with uncomplicated hypertension,” Journal of Human Hypertension, 22 (9), 648-651, Sep. 2008.
 
[2]  Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., et al., “The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report,” The Journal of the American Medical Association, 289 (19), 2560-2572, May 2003.
 
[3]  Suh, D.C., Kim, C.M., Choi, I.S., et al., “Trends in blood pressure control and treatment among type 2 diabetes with co-morbid hypertension in the United State: 1988-2004,” Journal of Hypertension, 27, 1908-1916, 2009.
 
[4]  Cushman, W.C., Evams. G.W., Byington, R.P., Goff, D.C., Jr., Grimm, R.H., Jr., et al., for the ACCORD Study Group, “Effects of intensive blood pressure control in type 2 diabetes mellitus,” New England Journal of Medicine, 362 (17), 1575-1585, Mar. 2010.
 
[5]  Cooper-Dehoff, R.M., Gong, Y., Handberg, E.M., Bavry, A.A., Dernado, S.J., et al., for the INVEST Study Group, “Tight blood pressure control and cardiovascular or outcomes among hypertensive patients with diabetes and coronary artery disease,” Journal of the American Medical Association, 304 (1), 61-68, Jul. 2010.
 
[6]  Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Kim, S.J., Koh, Y. and Shin, E.K., “Distinct vascular and metabolic effects of different classes of antihypertensive drugs,” International Journal of Cardiology, 140 (1), 73-81, Apr. 2010.
 
[7]  Grossman, E., Verdecchia, P., Shamiss, A., Angeli F., and Reboldi, G., “Diuretic treatment of hypertension,” Diabetes Care, 34 (Suppl 2), S313-S319, May 2011.
 
[8]  DiNicolantonio, J.J., “Hydrochlorothiazide: is it a wise choice?” Expert Opinion on Pharmacotherapy, 13 (6), 807-814, Apr. 2012.
 
[9]  Derosa, G. and Maffioli, P., “Drug safety evaluation of amlodipine,” Expert Opinion on Drug Safety, 10 (5), 795-804, Sep. 2011.
 
[10]  Patel, D. and Ganguly, B., “To study the nature of adverse drug reaction of amlodipine in hypertensive patients,” International Journal of Pharmacological Research, 2 (4), 30-33, Oct. 2010.
 
[11]  American Diabetes Association, “Standards of medical care in diabetes (Position Statement),” Diabetes Care, 34 (1), S1-S2, Jan. 2011.
 
[12]  Abengowe, C.U., Ezedinachi, E.N. and Balogun, M.O., “An open trial of lisinopril in mild to moderate hypertension in Nigeria,” West African Journal of Medicine, 16 (4), 218-222, Oct. 1997.
 
[13]  Brewster, L.M., van Montfrans, G.A. and Kleijnen, J., “Systematic review: Antihypertensive drug therapy in black patients,” Annals of Internal Medicine, 141 (8), 614-627, Oct. 2004.
 
[14]  Wright, J.T., Dunn, J.K., Cutler, J.A., Davis, B.R., Cushman, W.C., et al., “Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine and lisinopril,” The Journal of the American Medical Association, 293 (13), 1595-1608, Apr. 2005.
 
[15]  Odili, A.N., Ezeala-Adikaibe, B., Anisiuba, B.C., Kamdem, M.M., Ndiaye, M.B., Ijoma, C.K. and Kaptue, J., for the Newer versus Older Antihypertensive Agents in African Hypertension, “Progress report on the first sub-Saharan trial of newer versus older antihypertensive drugs in native black patients,” BioMed Central Trials, 13, 59, 2012.
 
[16]  Opadijo, O.G. and Omotosho, A.B.O., “Blood sugar profile in mild to moderate systemic hypertensives on thiazide diuretics whose blood pressure is well controlled,” Nigerian Journal of Medicine, 5, 48-50, 1996.
 
[17]  Okoro, E.O. and Oyejola, B.A., “Long term effects of hydrochlorothiazide on diabetic control and blood pressure in Nigerians,” Kuwait Medical Journal, 37 (1), 18-21, Mar. 2005.
 
[18]  Alebiosu, C.O., “Antidiabetics/antihypertensives prescription profile in OSUTH, Sagamu and environment,” Nigerian Journal of Clinical Practice, 7 (1), 15-20, Jan. 2004.
 
[19]  Dagogo-Jack, S., “Survey of diabetes and patient mortality in Port Harcourt, Nigeria,” Oriental Journal of Medicine 3, 37-41, 1991.
 
[20]  Iyalomhe, G.B.S., Omogbai, E.K.I. and Ozolua, R.I., “Antihypertensive and some biochemical effects of hydrochlorothiazide and furosemide in some Nigerians,” Journal of Medical Sciences, 7 (6), 977-983, Aug. 2007.
 
[21]  Iyalomhe, G.B.S., Omogbai, E.K.I., Ozolua, R.I., Dada, F.L. and Iyalomhe, O.O.B., “Electrolyte profiles in Nigerian patients with essential hypertension,” African Journal of Biotechnology, 7 (10), 1404-1408, May 2008.
 
[22]  Akinkugbe, O.O., “Current epidemiology of hypertension in Nigeria”. Archives of Ibadan Medicine, 1, 3-5, 2003.
 
[23]  Pickering, T.G., Hall, J.E., Appel, L.J., Falkner, B.E., Graves, J., et al., “Recommendations for blood pressure measurement in humans and experimental animals Part 1: blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research,” Hypertension, 45 (1), 142-161, Jan. 2005.
 
[24]  Sherabi, Y., Illan, R., Kamari, Y., et al., “Diuretic induced hyponatremia in elderly hypertensive women,” 16, 631-632, 2002.
 
[25]  Sica, D.A., Carter, B., Cushman, W. and Hamm, L., “Thiazide and loop diuretics,” Journal of Clinical Hypertension, 13 (9), 639-642, Sep. 2011.
 
[26]  Duarte, J.D. and Cooper-DeHoff, R.M., “Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics,” Expert Review in Cardiovascular Therapy, 8 (6), 793-802, Jun. 2010.
 
[27]  Siegel, D. and Swislocki, A.L.M., “Hypertensive treatment in patients with metabolic syndrome,” Metabolic Syndrome Related Disorders, 8 (2), 95-104, 2010.
 
[28]  Epstein, B.J., Vogel, K. and Palmer, B.F., “Dihydropyridine calcium channel antagonists in the management of hypertension,” Drugs, 67 (9), 1309-1327, 2007.